Age-dependent association of gut bacteria with coronary atherosclerosis: Tampere Sudden Death Study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 28 01 2019
accepted: 05 08 2019
entrez: 23 8 2019
pubmed: 23 8 2019
medline: 5 3 2020
Statut: epublish

Résumé

The gut microbiome is thought to remain stable into old age. Gut bacteria and their translocation may play a role in the development of coronary heart disease (CHD) by modulating cholesterol levels and immune responses, as well as by producing toxic metabolites and bacterial endotoxins. The association of changes in the gut microbiome with the severity of coronary atherosclerosis and the ability of gut bacteria themselves to translocate into coronary plaques has not been studied. As a part of the Tampere Sudden Death Study, we measured age-dependent changes in the relative ratios of major intestinal bacterial communities (Bacteroides species [spp.], the Clostridium leptum group, the Clostridium coccoides group, Bifidobacterium spp., Enterobactericeae, Lactobacillus spp.) and Streptococcus spp. in both feces and coronary plaques of the same male autopsy cases (n = 67, age range 44-95) using real-time quantitative PCR (qPCR). The area of coronary atherosclerotic lesions were measured by computer-assisted morphometry. Fecal bacterial DNA measurements from healthy volunteers served as a control for gut bacterial analyses of autopsy cases. The relative amount of bacterial DNA in a sample was determined with the comparative Cq method. The relative ratios of fecal Lactobacillus spp., Bifidobacterium spp., the Clostridium coccoides group, and Bacteroides spp. did not differ between controls and autopsy cases and showed no age-dependence. In contrast, the ratios of the Clostridium leptum group, Enterobactericeae, and Streptococcus spp. increased with age. Elevated relative ratios of fecal Enterobactericeae associated with a larger coronary plaque fibrotic area (p = 0.001), and the Clostridium leptum group with a larger calcification area (p = 0.015). Intestinal bacterial DNA could be amplified in 67.6% of the coronary plaques, the most common being Streptococcus spp. (41.0%), followed by Enterobactericeae (12.1%), Clostridium leptum (2.4%), and Lactobacillus spp. (2.4%). The percentages of Streptococcus spp. DNA decreased, and those of Enterobactericeae increased in coronary plaques along with age. DNA of the Clostridium leptum group and pathogenic Enterobactericeae increase in the gut microbiome with age and can be detected in the same individual's coronary plaques along with pathogenic Streptococcus spp., associating with more severe coronary atherosclerosis.

Sections du résumé

BACKGROUND
The gut microbiome is thought to remain stable into old age. Gut bacteria and their translocation may play a role in the development of coronary heart disease (CHD) by modulating cholesterol levels and immune responses, as well as by producing toxic metabolites and bacterial endotoxins. The association of changes in the gut microbiome with the severity of coronary atherosclerosis and the ability of gut bacteria themselves to translocate into coronary plaques has not been studied.
MATERIALS AND METHODS
As a part of the Tampere Sudden Death Study, we measured age-dependent changes in the relative ratios of major intestinal bacterial communities (Bacteroides species [spp.], the Clostridium leptum group, the Clostridium coccoides group, Bifidobacterium spp., Enterobactericeae, Lactobacillus spp.) and Streptococcus spp. in both feces and coronary plaques of the same male autopsy cases (n = 67, age range 44-95) using real-time quantitative PCR (qPCR). The area of coronary atherosclerotic lesions were measured by computer-assisted morphometry. Fecal bacterial DNA measurements from healthy volunteers served as a control for gut bacterial analyses of autopsy cases. The relative amount of bacterial DNA in a sample was determined with the comparative Cq method.
RESULTS
The relative ratios of fecal Lactobacillus spp., Bifidobacterium spp., the Clostridium coccoides group, and Bacteroides spp. did not differ between controls and autopsy cases and showed no age-dependence. In contrast, the ratios of the Clostridium leptum group, Enterobactericeae, and Streptococcus spp. increased with age. Elevated relative ratios of fecal Enterobactericeae associated with a larger coronary plaque fibrotic area (p = 0.001), and the Clostridium leptum group with a larger calcification area (p = 0.015). Intestinal bacterial DNA could be amplified in 67.6% of the coronary plaques, the most common being Streptococcus spp. (41.0%), followed by Enterobactericeae (12.1%), Clostridium leptum (2.4%), and Lactobacillus spp. (2.4%). The percentages of Streptococcus spp. DNA decreased, and those of Enterobactericeae increased in coronary plaques along with age.
CONCLUSIONS
DNA of the Clostridium leptum group and pathogenic Enterobactericeae increase in the gut microbiome with age and can be detected in the same individual's coronary plaques along with pathogenic Streptococcus spp., associating with more severe coronary atherosclerosis.

Identifiants

pubmed: 31437200
doi: 10.1371/journal.pone.0221345
pii: PONE-D-19-02635
pmc: PMC6705803
doi:

Substances chimiques

DNA, Bacterial 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221345

Déclaration de conflit d'intérêts

We have the following interests: Sari Tuomisto, Terho Lehtimäki and Pekka J. Karhunen have been employed by Fimlab Laboratories Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Références

Gastroenterology. 1999 Sep;117(3):577-83
pubmed: 10464133
Curr Issues Mol Biol. 2002 Jan;4(1):13-8
pubmed: 11838943
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Microbiol. 2002 Sep;40(9):3449-54
pubmed: 12202592
J Clin Microbiol. 2003 Feb;41(2):863-6
pubmed: 12574302
BMC Biotechnol. 2004 Jul 13;4:14
pubmed: 15251044
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23
pubmed: 15505215
Clin Med Res. 2005 Aug;3(3):176-85
pubmed: 16160072
J Biomed Biotechnol. 2005;2005(3):248-53
pubmed: 16192683
Circulation. 2006 Feb 21;113(7):929-37
pubmed: 16490835
J Am Coll Cardiol. 2007 Oct 16;50(16):1561-9
pubmed: 17936155
Infect Immun. 2008 Aug;76(8):3360-73
pubmed: 18474643
Eur J Clin Invest. 2008 Nov;38(11):857-62
pubmed: 19021704
FEMS Microbiol Ecol. 2009 Jun;68(3):351-62
pubmed: 19302550
Biochimie. 2011 Jan;93(1):39-45
pubmed: 20433893
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4586-91
pubmed: 20571116
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4592-8
pubmed: 20937873
Nature. 2011 May 12;473(7346):174-80
pubmed: 21508958
Circ Res. 2012 Apr 13;110(8):1097-108
pubmed: 22499900
Br J Nutr. 2012 Sep;108(5):801-9
pubmed: 22717075
Nature. 2012 Sep 13;489(7415):242-9
pubmed: 22972297
Endocr Metab Immune Disord Drug Targets. 2012 Dec;12(4):361-7
pubmed: 23017185
Nat Commun. 2012;3:1245
pubmed: 23212374
Circulation. 2013 Mar 19;127(11):1219-28, e1-6
pubmed: 23418311
J Forensic Sci. 2013 Jul;58(4):910-6
pubmed: 23550887
N Engl J Med. 2013 Apr 25;368(17):1575-84
pubmed: 23614584
Aging Clin Exp Res. 2014 Apr;26(2):183-91
pubmed: 24243034
Atherosclerosis. 2013 Dec;231(2):456-61
pubmed: 24267266
Gut Pathog. 2013 Nov 25;5(1):35
pubmed: 24267574
BMC Gastroenterol. 2014 Feb 24;14:40
pubmed: 24564202
Benef Microbes. 2014 Sep;5(3):235-46
pubmed: 24889891
J Intern Med. 2015 Jun;277(6):717-26
pubmed: 25382824
Microb Ecol Health Dis. 2015 Feb 02;26:26050
pubmed: 25651996
World J Clin Cases. 2015 Feb 16;3(2):156-62
pubmed: 25685762
Nutrition. 2016 Jun;32(6):620-7
pubmed: 26946974
Int J Mol Sci. 2016 Jul 29;17(8):
pubmed: 27483246
Ageing Res Rev. 2017 May;35:36-45
pubmed: 28109835
J Vasc Surg. 2018 Jun;67(6):1902-1907
pubmed: 28847664
Curr Opin Biotechnol. 2018 Feb;49:140-147
pubmed: 28866243
Gut. 1998 Jan;42(1):29-35
pubmed: 9505882

Auteurs

Sari Tuomisto (S)

Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Fimlab Laboratories Ltd, Pirkanmaa Hospital District, Tampere, Finland.

Heini Huhtala (H)

Faculty of Social Sciences, Tampere University, Tampere, Finland.

Mika Martiskainen (M)

Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
National Institute for Health and Welfare, Tampere, Finland.

Sirkka Goebeler (S)

National Institute for Health and Welfare, Tampere, Finland.

Terho Lehtimäki (T)

Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Fimlab Laboratories Ltd, Pirkanmaa Hospital District, Tampere, Finland.

Pekka J Karhunen (PJ)

Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Fimlab Laboratories Ltd, Pirkanmaa Hospital District, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH